Verrustat Wart Remover

Description

VerruStat Liquid Wart Remover is presented in a 15 ml volume. The product is identified by the SPL Code 34089-3 and is packaged under the label 44577-020-15. Visual references for the product include an image of the bottle (VerruStatLiquidBottle.jpg) and an image of the box (VerruStatLiquidBox.jpg).

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by a rough, 'cauliflower-like' appearance, while plantar warts are specifically located on the bottom of the foot and disrupt the normal footprint pattern.

Dosage and Administration

The affected area should be washed or soaked and dried thoroughly prior to application. Wart remover liquid should be applied using the enclosed applicator. Subsequent applications may be reapplied over the existing application. This procedure should be repeated once or twice daily until the wart is completely removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin, infected or reddened areas, and should not be used by individuals with diabetes or those who exhibit poor blood circulation. Healthcare professionals are advised to instruct patients to seek medical attention if discomfort persists following use.

The product must not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes.

Due to its flammable nature, it is imperative to keep the product away from fire or flame. The bottle should be tightly capped and stored at room temperature, away from heat sources.

In the event of accidental contact with the eyes, it is crucial to flush the eyes with water for a minimum of 15 minutes. Additionally, inhalation of vapors should be avoided to prevent respiratory irritation.

Side Effects

Patients should be aware that this product is for external use only and should not be applied to irritated skin, infected or reddened areas, or on individuals with diabetes or poor blood circulation. It is imperative to avoid using the product on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

In the event that discomfort persists after application, patients are advised to consult their healthcare provider. The product is flammable; therefore, it should be kept away from fire or flame. To ensure safety, the bottle should be tightly capped and stored at room temperature, away from heat sources.

If the product accidentally comes into contact with the eyes, it is recommended to flush the eyes with water for at least 15 minutes. Additionally, patients should avoid inhaling vapors associated with the product.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Verrustat Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use has not been specifically addressed in the prescribing information. There are no recommended age ranges, dosing differences, safety concerns, or special precautions for pediatric patients, including children and adolescents. Healthcare professionals should exercise caution when considering the use of this medication in the pediatric population due to the lack of data.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Close monitoring is recommended to ensure safety and efficacy in this population.

Pregnancy

The safety of this product during pregnancy has not been established. Pregnant patients or those planning to become pregnant should not use this product without consulting a healthcare provider. Potential risks to the fetus are not well characterized; therefore, caution is advised. It is recommended that healthcare providers be consulted for any necessary dosage modifications if a patient becomes pregnant while using this product. Special precautions should be taken to use this product only if clearly needed, ensuring that the benefits outweigh the risks during pregnancy.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. The effects on breastfed infants have not been established, and further research may be necessary to determine safety and efficacy in this population.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may involve maintaining airway patency, providing supplemental oxygen, and ensuring hemodynamic stability. Activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent, provided there are no contraindications.

Healthcare professionals should also consult local poison control centers or toxicology experts for guidance on specific antidotes or additional interventions that may be appropriate based on the clinical scenario. Continuous monitoring and supportive care are critical until the patient is stabilized.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with unauthorized access to the medication, ensuring that patients understand the necessity of proper storage practices.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It is essential to store the product at a temperature range of 20 degrees to 30 degrees Celsius (68 degrees to 86 degrees Fahrenheit) to maintain its efficacy and stability. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits to prevent degradation.

Additional Clinical Information

The medication is administered topically, with the recommended procedure to be repeated once or twice daily until the wart is completely removed, for a duration of up to 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Verrustat Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)